Skip to main content
Gulf Pharmaceutical Industries logo

Gulf Pharmaceutical Industries — Investor Relations & Filings

Ticker · JULPHAR ISIN · AEG000201018 Abu Dhabi Securities Exchange Manufacturing
Open in API
Filings indexed 364 across all filing types
Latest filing 2026-06-07 Regulatory Filings
Country AE United Arab Emirates
Listing Abu Dhabi Securities Exchange JULPHAR

About Gulf Pharmaceutical Industries

https://www.Julphar.net

Gulf Pharmaceutical Industries (Julphar) is a prominent pharmaceutical manufacturer and distributor. The company specializes in producing a diverse portfolio of medicines, vaccines, and consumer healthcare products, addressing a broad spectrum of health conditions. Julphar is recognized as one of the largest generic pharmaceutical manufacturers in the Middle East and North Africa, and a leading global producer of insulin. Utilizing internationally accredited, state-of-the-art facilities, it manufactures over one million medicine boxes daily, distributing products to more than 40 countries. The company's operations emphasize high quality and safety standards in its comprehensive manufacturing capabilities.

Recent filings

Filing Released Lang Actions
جلفار تفصح عن معلومه جوهريه
Regulatory Filings Classification · 75% confidence The document is a corporate announcement of “material information” regarding the completion status of the divestiture of certain retail and distribution assets by Gulf Pharmaceutical Industries. It does not contain financial statements, proxy materials, earnings data, or board changes, nor is it a US‐style merger proxy or tender‐offer filing. It is a standalone regulatory announcement disclosing the status of a transaction. Therefore it falls into the general Regulatory Filings (RNS) category as a miscellaneous regulatory disclosure.
2026-06-07 Arabic
Julphar announces a material disclosure
M&A Activity Classification · 85% confidence The document is a formal market disclosure by Gulf Pharmaceutical Industries announcing the completion (and pending completion) of transactions to sell retail and distribution channels (Health First Pharmacy chain and Scientific Pharmacy) to a third party. This constitutes a merger & acquisition-related announcement rather than a broader takeover proxy or tender‐offer filing. It is not a dividend, financing, share issue, or mere publication notice, but a direct transaction announcement of business assets. Thus, it fits best under M&A Activity (Code: TAR).
2026-06-07 English
تحديث بخصوص افصاح سابق
M&A Activity Classification · 82% confidence The document is a material information disclosure from Gulf Pharmaceutical Industries (Julphar) announcing the completion status of a previously disclosed acquisition transaction (sale of part of its retail and distribution channels to another healthcare group). This falls under corporate M&A activity disclosures (“استحواذ” = acquisition). It is not a full annual or interim report, earning release, or certification, but rather an update on an ongoing acquisition transaction. Therefore, it best matches the M&A Activity category (Code: TAR).
2026-06-07 Arabic
Update regarding previous disclosure
M&A Activity Classification · 87% confidence The document is a regulatory announcement titled “Disclosing Material Information” by Gulf Pharmaceutical Industries (Julphar) reporting the completion status of a transaction whereby Al Batha Healthcare Group LLC acquires certain retail/distribution channels of its subsidiary. This is an announcement of an asset acquisition/disposal, aligning with M&A activity disclosures rather than a general regulatory filing or financial report. Therefore, it fits best under M&A Activity (Code: TAR).
2026-06-07 English
إعادة التداول على أسهم شركة الخليج للصناعات الدوائية JULPHAR في 15 مايو 2026
Interim / Quarterly Report Classification · 95% confidence The document contains the full unaudited consolidated interim financial statements (statement of profit or loss, statement of financial position, cash flow, changes in equity, notes) for the three months ended 31 March 2026, along with an independent review report under IFRS IAS 34. It is a comprehensive interim/quarterly financial report, not merely an announcement or summary. Therefore, it qualifies as an Interim / Quarterly Report. Q1 2026
2026-05-15 Arabic
Resume trading on Gulf Pharmaceutical Industries-JULPHAR shares on 15 May 2026
Interim / Quarterly Report Classification · 90% confidence The document is titled “Interim Condensed Consolidated Financial Statements” for the three‐month period ended 31 March 2026, includes detailed interim profit or loss, comprehensive income, financial position, cash flows, changes in equity, notes, and an auditors’ review report under IAS 34. This aligns exactly with a quarterly/interim report rather than a full annual report or mere announcement. Q1 2026
2026-05-15 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.